David J. Mauro - Feb 9, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Medical Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 9, 2024
Transactions value $
-$19,090
Form type
4
Date filed
2/13/2024, 07:03 PM
Previous filing
Jun 7, 2023
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +6.04K +3.17% $0.00 197K Feb 9, 2024 Direct F1
transaction RXRX Class A Common Stock Award $0 +49.8K +25.29% $0.00 247K Feb 9, 2024 Direct F2
transaction RXRX Class A Common Stock Tax liability -$19.1K -1.89K -0.77% $10.09 245K Feb 9, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (RIght to Buy) Award $0 +99.5K $0.00 99.5K Feb 9, 2024 Class A Common Stock 99.5K $10.09 Direct F5
holding RXRX Stock Option (Right to Buy) 381K Feb 9, 2024 Class A Common Stock 381K $8.77 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vested immediately upon the grant date.
F2 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4 This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.